Cosciens BiopharmaCSCIF -5.24%62 Days Payable is 55.79 as of Mar. 2026, which is 50% below its 10-year median of 110.96. GuruFocus rates CSCIF with a GF Score™ of 62/100 and a GF Value™ of $2.35 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 708 Biotechnology companies, Cosciens Biopharma ranks worse than 51.98% on this metric.
The historical rank and industry rank for Cosciens Biopharma's Days Payable or its related term are showing as below:
CSCIF'
s Days Payable Range Over the Past 10 Years
Min: 24.39 Med: 110.96 Max: 168.67
Current: 102.88
During the past 13 years, Cosciens Biopharma's highest Days Payable was 168.67. The lowest was 24.39. And the median was 110.96.
CSCIF's Days Payable is ranked worse than 51.98% of 708
companies
in the Biotechnology industry
Industry Median: 113.56
vs CSCIF: 102.88
Cosciens Biopharma's Days Payable
declined
from Mar. 2025 (235.88) to Mar. 2026 (55.79).
It may suggest that Cosciens Biopharmaaccelerated paying its suppliers.
Cosciens Biopharma Days Payable Related Terms
Cosciens Biopharma Days Payable Historical Data
* Premium members only.
The historical data trend for Cosciens Biopharma's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSCIF vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Cosciens Biopharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosciens Biopharma Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cosciens Biopharma's Days Payable distribution charts can be found below:
* The bar in red indicates where Cosciens Biopharma's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Cosciens Biopharma's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cosciens Biopharma (CSCIF) has a Days Payable of 55.79 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Cosciens Biopharma and its competitors. This is 50% below median its historical median of 110.96. Over the past decade, Cosciens Biopharma's Days Payable has ranged from 24.39 to 168.67. According to the industry distribution chart, Cosciens Biopharma ranks #368 out of 708 companies in the Biotechnology industry, placing it in the top 52%.
Is Cosciens Biopharma's Days Payable too high?
Cosciens Biopharma's current Days Payable of 55.79 is 50% below median its 10-year median of 110.96. Over the past 10 years, this metric has ranged from a low of 24.39 to a high of 168.67. The Biotechnology industry median Days Payable is 113.56. Cosciens Biopharma's value of 55.79 is 50.9% below this industry median. Based on the distribution chart, Cosciens Biopharma ranks #368 out of 708 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Cosciens Biopharma has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cosciens Biopharma's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cosciens Biopharma ranks #368 out of 708 companies for Days Payable. This places Cosciens Biopharma in the lower half of its industry. The industry median Days Payable is 113.56. Cosciens Biopharma's value of 55.79 is 50.9% below this benchmark. Historically, Cosciens Biopharma's own Days Payable has ranged from 24.39 to 168.67 over the past decade. While the company's 10-year median is 110.96 vs. the industry median of 113.56, Cosciens Biopharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 708 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cosciens Biopharma's current Days Payable of 55.79 is 50.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Cosciens Biopharma and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cosciens Biopharma's current Days Payable is 55.79, which is 50% below median its own 10-year median of 110.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosciens Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Cosciens Biopharma (CSCIF) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.35, compared to a current price of $1.99 — trading 15.3% below its estimated fair value. The current Days Payable is 55.79, which is 50% below median its 10-year median of 110.96 and 50.9% below the Biotechnology industry median of 113.56. Cosciens Biopharma's overall GF Score™ is 62/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Cosciens Biopharma (CSCIF), the current Days Payable is 55.79 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosciens Biopharma (CSCIF) Overvalued in 2026?
Based on GuruFocus' analysis, Cosciens Biopharma stock appears to be undervalued.
The current stock price of $1.99 is trading 15.3% below its estimated GF Value™ of $2.35.
GuruFocus considers Cosciens Biopharma to be Modestly Undervalued.
Key valuation signals for CSCIF:
Days Payable: 55.79 (50% below median its 10-year median of 110.96)
GF Value™: $2.35 vs. price of $1.99 (15.3% below fair value)
Industry Position: 50.9% below the Biotechnology median (#368 of 708)
No single metric tells the full story. See the CSCIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing pharmaceutical and diagnostic products and active ingredients for the healthcare and cosmetics industries. It operates through two segments: Active Ingredient and Biopharmaceutical. The Active Ingredient segment, which generates maximum revenue, focuses on plant-based ingredients derived from oats and other renewable resources, including oat beta glucan, oat oil, and avenanthramides. The Biopharmaceutical segment focuses on the development and commercialization of therapeutics and diagnostic tests, including its product Macrilen, and advancing a pre-clinical pipeline targeting unmet medical needs, particularly in rare or orphan indications. It operates in Canada, Germany, the United States, and Austria.
62GF Score
Get the complete analysis for CSCIF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSCIF has been successfully added to your 
